Girding for a marketplace battle in oncology, Amgen Inc. offered encouraging data regarding its anemia product Aranesp (darbepoetin alfa), approved in September for dialysis and nondialysis patients with chronic liver failure and already being used off-label for cancer patients. (BioWorld Today) Read More
